Form 4: United Therapeutics CEO Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on April 25 and 26, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, reported changes in beneficial ownership of company stock.
- The transactions involved the exercise of stock options and subsequent sale of common stock on April 25 and 26, 2024.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- On both April 25 and 26, 3,600 stock options were exercised at a price of $129.49 per share.
- Following the exercise of options on April 25, shares were sold at weighted average prices ranging from $235.0236 to $236.8354.
- Following the exercise of options on April 26, shares were sold at weighted average prices ranging from $234.3597 to $236.34.
- After these transactions, Rothblatt directly owns 130 shares of common stock.
- Rothblatt also directly owns 295,469 stock options.
- The 10b5-1 plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the transactions are part of a pre-arranged trading plan and do not necessarily indicate a change in the executive's confidence in the company.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Industry Context
Executive stock transactions are common and closely monitored by investors. A 10b5-1 plan allows insiders to sell shares over a predetermined period, mitigating concerns about insider trading. The market will likely interpret these transactions in the context of the company's overall performance and future prospects.
Comparison to Industry Standards
- Executive compensation practices, including stock option grants and exercises, vary across the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
- The use of 10b5-1 trading plans is a standard practice among executives to manage their stock holdings and avoid accusations of insider trading.
- The size and frequency of these transactions are typical for executives at publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 2014-12-31 | Original exercisable date of stock options |
| 2023-08-04 | Date of establishment of the 10b5-1 trading plan |
| 2024-04-25 | Date of first reported transaction (exercise and sale of stock options) |
| 2024-04-26 | Date of second reported transaction (exercise and sale of stock options) |
| 2024-08-31 | Potential end date of the 10b5-1 trading plan |
| 2024-12-31 | Expiration date of the tranche of stock options under the 10b5-1 plan |
| 2024-04-29 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.